In this article, we will explore JWH-368 from different perspectives and with a multidisciplinary approach. JWH-368 is a topic that has sparked interest and debate throughout history, and its influence extends to different areas of society. We will analyze the various facets of JWH-368 through studies and research that have addressed its impact in the cultural, social, economic and political spheres. Additionally, we will examine how JWH-368 has evolved over time and how it continues to be relevant today. Through this exhaustive analysis, we hope to shed light on the importance and complexity of JWH-368, inviting critical and enriching reflection on this topic.
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H24FNO |
Molar mass | 385.482 g·mol−1 |
3D model (JSmol) | |
| |
|
JWH-368 (-naphthalen-1-ylmethanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 16 ± 1nM) and CB2 (Ki = 9.1 ± 0.7nM) receptors, binding ~1.76 times stronger to the CB2 receptor than to the CB1 receptor. JWH-368 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.[1]
In the United States JWH-368 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-368.[2][3][4][5]
In Canada, JWH-368 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.
In the United Kingdom, JWH-368 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.